BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36942414)

  • 1. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
    Yin X; He L; Guo Z
    Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.
    Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK
    Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
    Mao R; Hussein MS; He Y
    Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of single-cell omics for chimeric antigen receptor T cell therapy.
    Ghaffari S; Saleh M; Akbari B; Ramezani F; Mirzaei HR
    Immunology; 2024 Mar; 171(3):339-364. PubMed ID: 38009707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
    Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
    J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exhaustion of CAR T cells: potential causes and solutions.
    Kouro T; Himuro H; Sasada T
    J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering chimeric antigen receptor T cells for solid tumour therapy.
    Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
    Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
    Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
    Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
    Ahn T; Bae EA; Seo H
    Mol Ther; 2024 Jun; 32(6):1617-1627. PubMed ID: 38582965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
    Kagoya Y
    Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
    Abbott RC; Cross RS; Jenkins MR
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.
    Singh AK; Malviya R; Singh A; Sundram S; Mishra S
    Curr Cancer Drug Targets; 2023; 23(3):199-210. PubMed ID: 36173082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.